USANA Health Sciences Inc
F:USJ

Watchlist Manager
USANA Health Sciences Inc Logo
USANA Health Sciences Inc
F:USJ
Watchlist
Price: 16.3 EUR 0.62% Market Closed
Market Cap: €313.6m

Wall St Price Targets

USJ Price Targets Summary
USANA Health Sciences Inc

Wall Street analysts forecast USJ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for USJ is 38.61 EUR with a low forecast of 38.23 EUR and a high forecast of 39.75 EUR.

Lowest Forecast
Price Target
38.23 EUR
135% Upside
Average Forecast
Price Target
38.61 EUR
137% Upside
Highest Forecast
Price Target
39.75 EUR
144% Upside
USANA Health Sciences Inc Competitors:
Price Targets
AOF
Atoss Software AG
72% Upside

Revenue
Forecast

3% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
3% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is 5%.

Gross Profit
Forecast

3% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
3% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 2 years is 2%.

Operating Income
Forecast

-3% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
-3% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been -3%. The projected CAGR for the next 2 years is 22%.

Pre-Tax Income
Forecast

-4% / Year
Past Growth
104% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-4% / Year
Past Growth
104% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been -4%. The projected CAGR for the next 1 year is 104%.

Net Income
Forecast

-6% / Year
Past Growth
119% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
-6% / Year
Past Growth
119% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been -6%. The projected CAGR for the next 2 years is 119%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is USJ's stock price target?
Price Target
38.61 EUR

According to Wall Street analysts, the average 1-year price target for USJ is 38.61 EUR with a low forecast of 38.23 EUR and a high forecast of 39.75 EUR.

What is the Revenue forecast for USANA Health Sciences Inc?
Projected CAGR
5%

Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is 5%.

What is the Gross Profit forecast for USANA Health Sciences Inc?
Projected CAGR
2%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 2 years is 2%.

What is the Operating Income forecast for USANA Health Sciences Inc?
Projected CAGR
22%

Over the last 14 years, the compound annual growth rate for Operating Income has been -3%. The projected CAGR for the next 2 years is 22%.

What is the Pre-Tax Income forecast for USANA Health Sciences Inc?
Projected CAGR
104%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been -4%. The projected CAGR for the next 1 year is 104%.

What is the Net Income forecast for USANA Health Sciences Inc?
Projected CAGR
119%

Over the last 14 years, the compound annual growth rate for Net Income has been -6%. The projected CAGR for the next 2 years is 119%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett